DSM recently announced that it will be taking its first steps into the cannabinoid API market via a commercial partnership with global pioneer in cannabinoid APIs, Brains Bioceutical. In our recent interview, Kelsey Achenbach – Senior Director Pharma and Medical Nutrition, DSM – explains why the company is extending its pharmaceutical portfolio to include high-quality cannabinoid actives, and how this is creating opportunities for Rx pharmaceutical manufacturers to expand into new therapeutic fields by innovating with cannabinoids.
View original source video by clicking here
When it comes to cannabis culture and products, few names ring off in the streets like Cookies. Its genetics have been used to create some